Roche wins Japan approval for personalised cancer drug Rozlytrek
ZURICH: Swiss drugmaker Roche on Tuesday won approval in Japan for Rozlytrek as the world's biggest maker of cancer drugs pushes ahead in personalised medicines that require a biomarker test to identify prospective patients.
Roche said Japan is the first country to approve Rozlytrek, also known as entrectinib, targeting people with NTRK fusion-positive solid tumours, across 10 different tumour types, including those with central nervous system metastases.
Read Also: Roche appoints Thomas Schinecker as new head of $13 billion diagnostics unit
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here